跳至主要内容
临床试验/NCT04951882
NCT04951882Unknown早期 1 期

Transplatation of Human Umbilcal Cord Derived Mesenchyamal Stem Cells in Acute Lung Injury: a Single Center Prospective Clinical Research

Second Affiliated Hospital, School of Medicine, Zhejiang University1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2021年6月9日最近更新:
适应症
干预措施

试验速览

阶段
早期 1 期
发起方
入组人数
30
试验地点
1
主要终点
PaO2/FiO2

研究概览

简要总结

The patients suffered from acute lung ininjury (200<PaO2/FiO2 ≤ 300) will be divided into two groups: MSCs-treated group: patients are treated by intravenous injection of hUC-MSCs suspention ; control group: patients were treated with vehicle(Albumin) . The standard Therapies of acute lung injury were the same in both groups. In the following-up days, all the patients were monitored by the same items to evaluate the therapeutic effects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •1.≤ 3 days (72h)
  • •2.Age ≥18 years, ≤65 years
  • •3.200<PaO2/FiO2 ≤ 300
  • •4.Chest X-ray/chest CT : infiltrates of both lungs
  • •5.Need assisted ventilation (ventilation or high flow oxygen therapy)
  • •6.No left heart failure, pulmonary edema
  • •7.Agree to participate and signe an informed consent

排除标准

  • •1.Life expectancy <3 months due to non-respiratory failure
  • •2.Patients receiving extracorporeal membrane oxygenation support therapy(ECMO),high frequency oscillatory ventilation
  • •3.History of HIV, malignant tumors, or impaired immune function
  • •4.Patients accepted major surgery in the past 14 days (such as tumor removal, thoracotomy, heart surgery, abdominal surgery, intracranial surgery, or surgery for more than 3 hours, etc.)
  • •5.Pregnancy
  • •6.Have a serious concomitant disease
  • •7.Unable to follow-up
  • •8.History of severe allergic reactions or allergy to saline and serum
  • •9.Already participated in another clinical study within 12 weeks
  • •10.Pulmonary edema caused by other underlying diseases

研究组 & 干预措施

hUC-MSCs treatment

Placebo Comparator

Patients of acute lung injury will be treated by suspention of hUC-MSCs and albumin combined with standard therapies.

干预措施: human derived umbilical cord derived mesenchymal stem cells (Biological)

non-cell therapy

No Intervention

Patients of acute lung injury will be treated by vehicle (albumin) combined with standard therapies.

结局指标

主要结局

PaO2/FiO2

时间窗: Day 28

Oxygenation index

PaO2/FiO2

时间窗: Day 14

Oxygenation index

PaO2/FiO2

时间窗: Day 3

Oxygenation index

PaO2/FiO2

时间窗: Day 7

Oxygenation index

次要结局

  • the days of ventialtion and hospital stay(Day 28)
  • the days of ventialtion and hospital stay(Day 3)
  • the days of ventialtion and hospital stay(Day 7)
  • the days of ventialtion and hospital stay(Day 14)

研究者

发起方
Second Affiliated Hospital, School of Medicine, Zhejiang University
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验